Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
TOKYO, Dec 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed […]